Searchable abstracts of presentations at key conferences in endocrinology

ea0021p335 | Steroids | SFEBES2009

Diagnostically difficult Cushing’s syndrome in a pharmacy student

Marath Haris , Dhatariya Ketan

Twenty-two years old pharmacy student was urgently referred from primary care with a history of recent weight gain of 15 kg and an elevated 24 h urinary free cortisol (UFC) of 4517 nmol/l (<330). Clinically she described increasing hirsutism, low mood, loss of libido and symptoms suggestive of proximal myopathy.Her past medical history included recurrent low impact wrist fractures, asthma, PCOS, depression and epilepsy.On exami...

ea0021p53 | Clinical practice/governance and case reports | SFEBES2009

An unusual presentation of polyendocrinopathy

Venu Maya , Marath Haris , Swords Francesca

A 52-year-old gentleman was referred for the evaluation of hypercalcaemia. He gave a four week history of feeling generally unwell with dizziness, abdominal discomfort, weight loss, nausea and vomiting. He was an ex-heavy smoker and was on Lithium for about 20 years for bipolar disorder. He had had a recent admission to hospital with sepsis, secondary to chest infection, with a brief ITU stay and was discharged only 3 weeks prior to the onset of current illness.<p class="a...

ea0065p179 | Metabolism and Obesity | SFEBES2019

Continuous subcutaneous insulin infusion (CSII): a trust-wide audit

Tauni Rahat Ali , Marath Haris , Shipp Maxine , Griggs Susan , Orriss Karen , Davey Larissa , Hunt Mandy

Aims and objectives: Continuous subcutaneous insulin infusion (CSII) has been in clinical practice since 1970s. NICE guidance (2008) recommends CSII in adults with type 1 diabetes (T1DM) if attempts to achieve target HbA1c with multiple daily injections (MDIs) result in disabling hypoglycaemia or HbA1c levels remain above 69 mmol/mol. The aim of our audit was to check compliance of our service against NICE guidance, and to see if CSII improved glycaemic control and/or hypoglyc...